Abiopharma

🔍 Ganot Ilan (Executive)

Company: Solid Biosciences Inc. (SLDB)

Report Date: 2026-01-03

Detailed Transactions and Holdings:

• Acquired 2,994 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | shares_owned_after: 18,331.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,053 shares of Common Stock at $5.43 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 17,278.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: H | shares_owned_after: 95,413.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-03 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 19,394.00 | Footnotes: F4
• Sold 2,994 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-03 | Code: M | equity_swap_involved: false | shares_owned_after: 2,994.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Restricted stock units convert to common stock on a one-for-one basis.
• F2: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot.
• F3: Represents 91,371 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
• F4: Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
• F5: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.